Ipsen Hungry For More Deals After Swallowing Epizyme
$247m Upfront For Lymphoma Drug Tazverik
Ipsen CEO David Loew recently told Scrip that a return to more rational valuations for biotechs should led to more deals. The Epizyme acquisition could be the first of many by the French group this year.
